OKYO Pharma Limited is a bio-pharmaceutical company focused on the discovery and development of first-in-class pharmaceutical therapies to treat inflammatory eye diseases including dry eye and ocular pain. The company was founded in 2019 by Gary Jacob, a serial entrepreneur with over 20 years of experience in the pharmaceutical industry. OKYO Pharma is headquartered in London, UK, with offices in New York City, USA.
The company's lead drug candidate is OK-101, a novel class of chemerin receptor agonist that produces an anti-inflammatory action and reduction in neuropathic pain. Chemerin is a recently discovered signaling molecule that plays a role in inflammation and pain. OK-101 is designed to specifically target the chemerin receptor in the eye, with the goal of providing a more effective and tolerable treatment for dry eye and ocular pain than currently available therapies.
OKYO Pharma is currently conducting a Phase 1 clinical trial of OK-101 in patients with dry eye disease. The trial is expected to be completed in 2023. If the trial is successful, OKYO Pharma plans to conduct a Phase 2 clinical trial in patients with ocular pain.
In addition to OK-101, OKYO Pharma is also developing a pipeline of other drug candidates for the treatment of inflammatory eye diseases. The company is targeting a range of diseases, including dry eye, non-infectious anterior uveitis, and allergic conjunctivitis.
OKYO Pharma is backed by a strong team of scientists and clinicians with extensive experience in the pharmaceutical industry. The company is also supported by a number of leading venture capital firms.
OKYO Pharma is well-positioned to become a leading developer of treatments for inflammatory eye diseases. The company has a strong pipeline of drug candidates, a talented team, and the financial backing to succeed.
Here are some additional details about OKYO Pharma: